Risankizumab versus adalimumab for moderate-to-severe plaque psoriasis: a critical appraisal.

Like Comment

Patients with moderate-to-severe plaque psoriasis have greatly benefited from the availability of biologics. However, treatment-selection can be challenging and it is important that with growing numbers of biologics available, head-to-head trials comparing efficacy and safety outcomes are undertaken. Most head-to-head trials comparing newer classes of biologics to tumour necrosis factor-α inhibitors have compared with etanercept, which is less commonly used than adalimumab.

Click here to read the full article @ The British journal of dermatology

Go to the profile of ClinOwl


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
2212 Contributions
0 Following

No comments yet.